BioSpace News Archive

CN Bio today announced that the U.S. Food and Drug Administration (FDA) and CN Bio have expanded their collaboration for the second time, with new research aiming to evaluate multi-organ MPS and their applications using the PhysioMimix™ Multi-organ System.

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that both companies have entered into a definitive merger agreement under which Calyxt and Cibus will merge in an all-stock transaction.

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the fourth quarter and full-year 2022.

TTP plc (TTP), a leading independent technology and product development company, has today announced the launch of Cellular Origins, a TTP Company.

A study published in the journal Antibiotics found that photodisinfection, using a methylene blue-based photosensitizer in combination with a specific wavelength of light, effectively eradicated pathogens commonly found on arthroplasty materials used in joint replacements

The Muscular Dystrophy Association (MDA) and PathMaker Neurosystems Inc. announced today an investment of $600,000 through the MDA Venture Philanthropy (MVP) program to PathMaker to advance its work in amyotrophic lateral sclerosis (ALS).

THREAD , the leading technology and consulting service provider enabling electronic clinical outcome assessments (eCOA) and decentralized clinical trials (DCTs), announced today its five-year collaboration with innovative global health care company, Sanofi.

NEXGEL, Inc. announced today the appointment of Scott Henry, CFA as a new independent director to the Company’s Board of Directors (the “Board”), effective immediately.

Accuray Incorporated (NASDAQ: ARAY) announced today that Auckland Radiation Oncology (ARO) is the first center in New Zealand to treat patients with the CyberKnife® System, a robotic radiation therapy device known for delivering treatments with sub-millimeter precision and accuracy in typically 1 to 5 outpatient sessions.

NewAmsterdam Pharma Company N.V. (Nasdaq:NAMS) (“NewAmsterdam” or the “Company”) today announced topline results from ROSE2, a Phase 2 clinical trial evaluating obicetrapib, the company’s oral, low-dose and once-daily cholesteryl ester transfer protein (“CETP”) inhibitor, in combination with ezetimibe as an adjunct to high-intensity statin therapy.